title: Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
abstract: BACKGROUND
  Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation permanent polymer drug-eluting stents. We aimed to further investigate the effects of a biodegradable polymer biolimus-eluting stent compared with a durable polymer-coated sirolimus-eluting stent in a population-based setting.
  
  
  METHODS
  This randomised, multicentre, all-comer, non-inferiority trial was undertaken at three sites across western Denmark. Eligible patients were aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes, and at least one coronary artery lesion (>50% diameter stenosis). We randomly assigned patients (1:1) using an independently managed computer-generated allocation sequence to receive either a biolimus-eluting biodegradable polymer stent (Nobori, Terumo, Tokyo, Japan) or a sirolimus-eluting permanent polymer stent (Cypher Select Plus, Cordis, Johnson & Johnson, Warren, NJ, USA). The primary endpoint was a composite of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (target vessel revascularisation) at 9 months, analysed by intention to treat (non-inferiority margin of 0·02). This trial is registered with ClinicalTrials.gov, number NCT01254981.
  
  
  RESULTS
  From July, 2009, to January, 2011, we assigned 1229 patients (1532 lesions) to receive the biolimus-eluting stent and 1239 (1555 lesions) to receive the sirolimus-eluting stent. One patient was lost to follow-up because of emigration. Intention-to-treat analysis showed that 50 (4·1%) patients who were assigned the biolimus-eluting stent and 39 (3·1%) who were assigned the sirolimus-eluting stent met the primary endpoint (risk difference 0·9% [upper limit of one-sided 95% CI 2·1%]; p(non-inferiority)=0·06). Significantly more patients in the biolimus-eluting stent group had definite stent thrombosis at 12 months than did those in the sirolimus-eluting stent group (9 [0·7%] vs 2 [0·2%], risk difference 0·6% [95% CI 0·0-1·1]; p=0·034). Per-protocol analysis showed that 45 (3·8%) of 1193 patients who received a biolimus-eluting stent and 39 (3·2%) of 1208 who received a sirolimus-eluting stent met the primary endpoint (risk difference 0·5% [upper limit of one-sided 95% CI 1·8%]; p(non-inferiority)=0·03).
  
  
  CONCLUSIONS
  At 1 year follow-up, the biodegradable polymer biolimus-eluting Nobori stent did not improve clinical results compared with a first-generation sirolimus-eluting stent. We will need to obtain long-term data before we can make recommendations for the role of this biolimus-eluting stent in routine clinical practice.
  
  
  BACKGROUND
  Terumo and Cordis (Johnson & Johnson).
authors: Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark. evald.christiansen@dadlnet.dk
authors: Evald Høj
authors: EH
authors: Christiansen
authors: Lisette Okkels
authors: LO
authors: Jensen
authors: Per
authors: P
authors: Thayssen
authors: Hans-Henrik
authors: HH
authors: Tilsted
authors: Lars Romer
authors: LR
authors: Krusell
authors: Knud Nørregaard
authors: KN
authors: Hansen
authors: Anne
authors: A
authors: Kaltoft
authors: Michael
authors: M
authors: Maeng
authors: Steen Dalby
authors: SD
authors: Kristensen
authors: Hans Erik
authors: HE
authors: Bøtker
authors: Christian Juhl
authors: CJ
authors: Terkelsen
authors: Anton Boel
authors: AB
authors: Villadsen
authors: Jan
authors: J
authors: Ravkilde
authors: Jens
authors: J
authors: Aarøe
authors: Morten
authors: M
authors: Madsen
authors: Leif
authors: L
authors: Thuesen
authors: Jens Flensted
authors: JF
authors: Lassen
mesh_terms: D020341:Absorbable Implants; D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy*; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D003328:Coronary Thrombosis / Q000453:epidemiology / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011108:Polymers; D019233:Retreatment / Q000706:statistics & numerical data; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; D011108:Polymers; D001241:Aspirin; C518022:umirolimus; D020123:Sirolimus